Contrast-enhanced Ultrasound With Perfluorobutane and Sulfur Hexafluoride for Hepatocellular Carcinoma
Not Applicable
Completed
- Conditions
- Hepatocellular Carcinoma
- Registration Number
- NCT04847726
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
Intra-individual comparison of diagnostic performance of CEUS With perfluorobutane and sulfur hexafluoride for HCC in high-risk Individuals, and their role in the diagnostic algorithm of HCC.
- Detailed Description
The investigators would compare the diagnostic performance for HCC at high-risk individuals between both USG contrast agents.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 110
Inclusion Criteria
- high-risk for HCC (liver cirrhosis, chronic hepatitis B)
- treatment-naive hepatic nodule (>= 1cm) on preceding CT, MR or ultrasound
Exclusion Criteria
- severe cardiopulmonary dysfunction
- pregnancy
- refusal to enroll study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Diagnostic accuracy for HCC: non-inferiority test up to 3 months The per-lesion diagnostic accuracy for HCC of CEUS with perfluorobutane and sulfur hexafluoride using the same diagnostic criteria (arterial phase hyperenehancement with mild and late (≥ 60 sec) washout).
- Secondary Outcome Measures
Name Time Method Diagnostic performance of perfulorobutane enhanced USG using different definition of washout up to 3 months Per-lesion sensitivity and specificity for diagnosing HCC using different time windows for assessing washout in PFB-US
Trial Locations
- Locations (1)
Seoul National University Hospital
🇰🇷Seoul, Jongno-gu, Korea, Republic of
Seoul National University Hospital🇰🇷Seoul, Jongno-gu, Korea, Republic of